[{"orgOrder":0,"company":"Coripharma","sponsor":"Midas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"","productType":"Small molecule","year":"2020","type":"Licensing Agreement","leadProduct":"Raltegravir Potassium","moa":"","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Coripharma","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Tablet, Film Coated","sponsorNew":"Coripharma \/ Midas Pharma","highestDevelopmentStatusID":"10","companyTruncated":"Coripharma \/ Midas Pharma"}]

Find Clinical Drug Pipeline Developments & Deals by Coripharma

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          American Pharma Summit
                          Not Confirmed
                          American Pharma Summit
                          Not Confirmed

                          Details : Corifarma and Midas entered into an exclusive out-licensing cooperation for the European territory. The respective product, Raltegravir, can be launched in the EU in 2023 as a generic and is used in treatment of HIV/AIDS.

                          Brand Name : Raltegravir-Generic

                          Molecule Type : Small molecule

                          Upfront Cash : Undisclosed

                          September 23, 2020

                          Lead Product(s) : Raltegravir Potassium

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase III

                          Sponsor : Midas Pharma

                          Deal Size : Undisclosed

                          Deal Type : Licensing Agreement

                          blank